Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Published on January 9
Government incentives are reshaping the pharmaceutical landscape, creating clear winners amongst companies positioned for domestic manufacturing growth.
Major drug makers are committing multi-billion dollar investments to US-based production, driving demand for specialised manufacturing and supply chain partners.
The shift from overseas to domestic pharmaceutical manufacturing represents one of the most significant structural changes in healthcare in decades.
The US government is striking deals with major pharmaceutical companies, offering tariff exemptions in exchange for lower drug prices. This policy shift creates significant opportunities for companies involved in domestic pharmaceutical manufacturing and supply chains, as billions in investment flows toward onshoring critical healthcare production.
This collection includes two key types of companies: established pharmaceutical giants navigating new pricing agreements, and domestic manufacturers positioned to benefit from reshoring efforts. The trend spans contract manufacturing, logistics, medical devices, and specialised healthcare components essential for expanding US-based production.
Each company was handpicked based on their strategic positioning within this evolving landscape. From major pharmaceutical players like Eli Lilly and Bristol-Myers Squibb to specialised manufacturers like West Pharmaceutical Services, these stocks represent direct exposure to government incentives driving healthcare manufacturing back to American shores.
This basket's total market capitalisation is 1,481,736.7483 and is heavily anchored by a small number of very large-cap stocks. That concentration tends to give the basket a large-cap profile with lower expected volatility and more market-like behaviour.
LLY: $1.03T
MCK: $100.55B
BMY: $113.80B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+4
Here are a few of the assets in this group. Create an account to unlock the full list.
Eli Lilly & Co
LLY
Current Price
$1,193.66
As a leading global pharmaceutical company with a significant manufacturing and research presence in the US, Eli Lilly is central to government drug p...
As a leading global pharmaceutical company with a significant manufacturing and research presence in the US, Eli Lilly is central to government drug pricing negotiations and domestic production incentives.
McKesson
MCK
Current Price
$894.35
McKesson is a primary distributor of pharmaceuticals in the United States, making it a critical component of the domestic supply chain influenced by g...
McKesson is a primary distributor of pharmaceuticals in the United States, making it a critical component of the domestic supply chain influenced by government pricing agreements.
Bristol Myers Squibb
BMY
Current Price
$67.62
Bristol-Myers Squibb is a major biopharmaceutical company with substantial US operations, positioning it as a key participant in federal drug pricing ...
Bristol-Myers Squibb is a major biopharmaceutical company with substantial US operations, positioning it as a key participant in federal drug pricing discussions and onshoring initiatives.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
On average, analysts expect assets in this group to grow 23.81% over the next year.
13 of 14 assets in this group are rated Buy by professional analysts.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+23.81%
